Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7277-7281

  Morrissey, Catherine ^a   Martinez, Alonso ^a   Zatyka, Malgorzata ^a   Agathanggelou, Angelo ^a   Honorio, Sofia ^a   Astuti, Dewi ^a   Morgan, Neil V ^a   Holger, Moch ^a   Richards, Frances M ^a   Latif, Farida ^a   Maher, Eamonn R ^a,a   Moch, Holger ^b   Schraml, Peter ^b   Kishida, Takeshi ^c   Yao, Masahiro ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CHROMOSOME 3P; CLEAR CELL CARCINOMA; GENE INACTIVATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 3; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY NEOPLASMS; LIGASES; MUTATION; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROTEINS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0035476868     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Histopathology and classification of renal cell tumors (adenomas oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics
2. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma
3. Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas
4. Histopathological cytogenetic and molecular characterization of renal cortical tumors
5. Allelotype of renal cell carcinoma
6. Loss of heterozygosity at the short arm of chromosome 3 in renal cell cancer correlates with cytological tumour type
7. Molecular genetic investigation of sporadic renal cell carcinoma: Analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22
8. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes
9. Isolation of the von Hippel-Lindau disease turnout suppressor gene
10. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma
11. Mutations of the VHL tumor suppressor gene in renal carcinoma
12. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinomas
13. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas
14. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis
15. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
16. Deletions of the short arm of chromosome 3 in solid tumours and the search for suppressor genes
17. Involvement of multiple loci on chromosome 3 in renal cell cancer development
18. Role of chromosome 3pl2-p21 tumour suppressor genes in clear cell renal cell carcinoma: Analysis of VHL-dependent and VHL-independent pathways of tumourigenesis
19. Definition of a tumor suppressor locus within human chromosome 3p21-p22
20. A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo
21. The FHIT gene spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint is abnormal in digestive tract cancers
22. Structure and expression of the human FHIT gene in normal and tumor cells
23. Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus
24. Absence or reduction of Fhit expression in most clear cell renal carcinomas
25. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas
26. Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis
27. A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in YACs
28. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes
29. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
30. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors
31. The RASSF1A locus in the 3p21.3 homozygous deletion region: Epigenetic inactivation in lung and breast cancer and suppression of the malignant phenotype
32. Allelic loss at the D9SI71 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma
33. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis
34. Allelic deletions in renal tumors: Histopathological correlations
35. Cytogenetic analysis of epithelial renal cell tumors: Relationship with a new histopathological classification
36. Analysis of 3p allelic losses in renal cell carcinomas: Comparison with cytogenetic results
37. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
38. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice
39. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched
40. Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion
41. CpG island methylator phenotype in colorectal cancer
42. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
43. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma
44. Mutations in the ras protooncogenes are rare events in renal cancer
45. The genetic locus NRC-1 within chromosome 3pl2 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation
46. The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering
47. Requirement of regulated activation of Ras for response of MDCK cells to hepatocyte growth factor/scatter factor
48. Hereditary and sporadic papillary renal carcinomas with c-MET mutations share a distinct morphologic phenotype